1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

08 Jan 2026
Admin
News Article

Dr Reddy’s Launches Hevaxin, India’s First DCGI-Approved Hepatitis E Vaccine

Dr Reddy’s Laboratories has launched Hevaxin, a recombinant hepatitis E vaccine, in India—marking a major step in preventive liver care.

Hevaxin is the only vaccine approved by the DCGI for active immunisation against hepatitis E virus (HEV) in adults aged 18–65 years in India.

Why This Matters?

Hepatitis E is not rare. It is deadly when it strikes vulnerable groups.

Global burden (WHO estimates):

~20 million infections annually
3.4 million illnesses
70,000 deaths
3,000 stillbirths

India-specific impact:

Up to 40% of acute hepatitis cases
15–45% of acute liver failure cases
Mortality can reach 67% in severe liver failure

This makes prevention—not treatment—the real bottleneck.

About Hevaxin

Hevaxin is a novel recombinant vaccine designed to prevent HEV infection.

Clinical evidence shows:

Protective efficacy against hepatitis E
Long-lasting immunity
Favourable immune response
Established safety and tolerability profile

It targets a disease with limited preventive options so far.

High-Risk Groups for Hepatitis E

Certain populations face disproportionately severe outcomes.

Highest-risk groups include:

Women of childbearing age
Patients with chronic liver disease
Immunocompromised individuals
Organ transplant candidates

In these groups, HEV can trigger acute-on-chronic liver failure with high fatality.

Policy and Public Health Alignment

The WHO has included the hepatitis E vaccine as the fifth vaccine under the International Coordinating Group (ICG) mechanism.

In India, Hevaxin aligns with the National Viral Hepatitis Control Programme, which aims to reduce hepatitis-related morbidity and mortality nationwide.

What Dr Reddy’s Is Saying?

M V Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy’s, highlighted the preventive gap.

He described Hevaxin as a first-in-class preventive option for a disease that remains lethal for liver patients. The launch also strengthens Dr Reddy’s expanding vaccine portfolio.

Partnerships and Distribution

Dr Reddy’s has partnered with:

Shenzhen Mellow Hope Pharm
Urihk Pharmaceutical

These partnerships will support marketing and distribution of Hevaxin across India.

Bottom Line

Hevaxin fills a critical gap in India’s hepatitis strategy. It offers the first DCGI-approved preventive option against hepatitis E. For high-risk patients, this could be the difference between recovery and liver failure.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!